Sorrento 
Welcome,         Profile    Billing    Logout  
 31 Products   1 Disease  31 Products   46 Trials   1437 News 
67 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cynviloq (paclitaxel polymeric micelle formulation) / Sorrento, Samyang Group, ImmunityBio
Randomized study of Genexol-PM combined with Cisplatin in advanced NSCLC, ChiCTR-IPR-15006252: A Randomized, Open, Multicenter Trial of Genexol-PM or Paclitaxel Injection combined with Cisplatin for first-line therapy of advanced Non-Small Cell Lung Cancer(NSCLC)

Recruiting
3
426
 
Genexol-PM+Cisplatin ;Paclitaxel Injection + Cisplatin
Guangdong General Hospital; Shanghai Chest Hospital; Jiangsu Cancer Hospital; Shanghai Yizhong Bio-technology Co., Ltd, self-financing
Non-Small Cell Lung Cancer(NSCLC)
 
 
NCT07009925: Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.

Not yet recruiting
2
38
NA
Ivonescimab 20mg/kg intravenous every 3 weeks, paclitaxel polymeric micelles ≤300mg/㎡intravenous every 3 weeks, platinum intravenous every 3 weeks
Jiangsu Cancer Institute & Hospital
Squamous Cell Lung Cancer
05/27
05/28
ChiCTR-ONC-14005123: Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced tomors

Completed
1
12
 
Genexol-PM
Jiangsu Cancer Hospital; None, self-financing
advanced tumor
 
 
NCT06936787: An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa

Recruiting
1
21
RoW
IGT001
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Retinitis Pigmentosa
12/25
12/27
NCT05300828: Safety of Genexol PM and Carboplatin as First-line Therapy in Ovarian Cancer

Completed
N/A
600
RoW
Genexl PM
Seoul National University Hospital, Samyang Biopharmaceuticals Corporation
Ovarian Cancer
04/22
12/22
resiniferatoxin (MCP-101) / Sorrento
NCT04885972: Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis

Active, not recruiting
2
124
US
Resiniferatoxin, RTX, Zilretta, triamcinolone acetonide, Placebo
Sorrento Therapeutics, Inc.
Osteoarthritis, Knee, Knee Osteoarthritis, Knee Pain Chronic
09/23
11/23
NCT05067257: Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer

Suspended
2
120
US
Resiniferatoxin, RTX, Placebo
Sorrento Therapeutics, Inc.
Pain, Intractable, Pain Cancer, Pain
06/27
12/27
NCT00804154: Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

Recruiting
1
45
US
Intrathecal Resiniferatoxin
National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Neurological Disorders and Stroke (NINDS), Sorrento Therapeutics, Inc.
Intractable Pain, Palliative Care
02/26
02/26
ZTlido (lidocaine patch 1.8%) / Sorrento
DLss, NCT06030297: Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.

Recruiting
N/A
301
US
Diode Laser fiber type Selective Stimulator, DLss, ZTlido 1.8 % Topical System, PeriCam PSI NR, speckle imager, Medoc Quantitative Sensory Testing, QST, Inactive Topical System, placebo patch
University of Utah, Stanford University, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)
Peripheral Neuropathy
08/25
08/25
Shan Ke Yu (socazolimab) / Lee's Pharm
NCT04359550: Study of ZKAB001 for Maintenance Therapy in Patients With High-grade Osteosarcoma After Adjuvant Chemotherapy

Not yet recruiting
3
362
NA
Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001), placebo
Lee's Pharmaceutical Limited
High-grade Osteosarcoma
06/22
06/23
ZKAB001-LEES-2020-07, NCT04878016: A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC

Completed
3
498
RoW
ZKAB001, Placebo, Carboplatin, Etoposide
Lee's Pharmaceutical Limited
Extensive-stage Small-cell Lung Cancer
10/23
10/23
NCT06459687: Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer

Recruiting
3
440
RoW
Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab, Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab
Lee's Pharmaceutical Limited
Cervical Cancer
09/27
09/28
ChiCTR2000028785: A multicenter, phase III, randomized, double-blind, placebo-controlled trial for recombinant human anti-PD-L1 monoclonal antibody (ZKAB001) for maintenance therapy after adjuvant chemotherapy in patients with high-grade osteosarcoma

Not yet recruiting
3
362
 
Intravenous infusion ;Intravenous infusion
Shanghai Sixth People's Hospital; Zhaoke (Guangzhou) Oncology Drug Co., Ltd., Self-finacing
Osteosarcoma
 
 
NCT03676985: A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade Osteosarcoma

Recruiting
1/2
15
RoW
ZKAB001 5mg/kg, PD-L1 monoclonal antibody, ZKAB001 10mg/kg, ZKAB001 15mg/kg
Lee's Pharmaceutical Limited
Osteosarcoma
02/20
06/23
NCT03676946: A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma

Recruiting
1/2
15
RoW
ZKAB001 5mg/kg, PD-L1 monoclonal antibody, ZKAB001 10mg/kg, ZKAB001 15mg/kg
Lee's Pharmaceutical Limited
Urothelial Carcinoma
02/20
06/23
NCT04460066: A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.

Active, not recruiting
1/2
70
RoW
anti-PD-L1 antibody, ZKAB001, Socazolimab Injection, albumin bound paclitaxel, ABRAXANE, cisplatin, placebo, radical resection of esophageal carcinoma
Lee's Pharmaceutical Limited
Esophageal Cancer
12/21
07/23
NCT04849260: Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma

Recruiting
1/2
54
RoW
Pexa-Vec combined with ZKAB001, ZKAB001 monotherapy
Lee's Pharmaceutical Limited
Local Progression or Metastatic Melanoma With Failed First-line Treatment
05/22
05/23
ChiCTR1800016649: Phase I+II clinical study protocol of recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)

Not yet recruiting
1
21
 
Intravenous infusion ;Intravenous infusion ;Intravenous infusion
the Sixth People's Hospital; Zhaoke (Guang Zhou) Oncology Pharmaceutical Limited, Self-finacing
Osteosarcoma
 
 
NCT03676959: A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Recurrent or Metastatic Cervical Cancer

Recruiting
1
101
RoW
ZKAB001 5mg/kg, PD-L1 monoclonal antibody, ZKAB001 10mg/kg, ZKAB001 15mg/kg
Lee's Pharmaceutical Limited
Cervical Cancer
05/22
10/22
NCT04603846: A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma

Active, not recruiting
1
20
RoW
anti-PD-L1 antibody, ZKAB001, albumin bound paclitaxel, ABRAXANE
Lee's Pharmaceutical Limited
Advanced Urothelial Carcinoma
10/22
08/23
NCT04346914: Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer

Recruiting
1
20
RoW
recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide
Lee's Pharmaceutical Limited
Extensive Stage Small Cell Lung Cancer
10/22
10/22
NCT04608786: A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer

Enrolling by invitation
1
10
RoW
ZKAB001 5mg/kg, PD-L1 monoclonal antibody, Capecitabine
Lee's Pharmaceutical Limited
Biliary Tract Cancer
12/22
12/23
ChiCTR2100042988: A single-arm, open phase Ib clinical study of ZKAB001 combined with capecitabine for adjuvant treatment of patients with malignant tumors of the biliary system

Recruiting
1
10
 
Regiments
Renji Hospital Affiliated to Medical College of Shanghai Jiaotong University; Renji Hospital Affiliated to Medical College of Shanghai Jiaotong University, Guangzhou Zhaoke Pharmaceutical Co., Ltd.
Malignant tumor of biliary system
 
 
Fujovee (abivertinib) / Sorrento
NCT03856697: Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

Not yet recruiting
3
406
RoW
Abivertinib Maleate Capsules, Placebo Gefitinib Tablets, Gefitinib Tablets, Placebo Abivertinib Maleate Capsules
Hangzhou ACEA Pharmaceutical Research Co., Ltd., Guangdong Provincial People's Hospital
Advanced Non-small Cell Lung Cancer
03/22
03/24
TRUMP, NCT03574402: Phase II Umbrella Study Directed by Next Generation Sequencing

Recruiting
2
400
RoW
Avitinib Maleate, AC0010, Afatinib, Giotrif, Crizotinib, Xalkori, X-396, ensartinib, Chidamide, Epidaza, Pyrotinib Maleate, SHR1258, AZD3759, Pirotinib, KBP-5209, Nimotuzumab, Pemetrexed, LY231514, Cisplatin, CDDP, Sintilimab, Gemcitabine, LY188011, Carboplatin, NSC 241240
Guangdong Association of Clinical Trials, Chinese Thoracic Oncology Group
Carcinoma, Non-Small-Cell Lung
12/22
12/24
Maverick, NCT05361915: Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer

Suspended
2
100
US
Abivertinib, STI-5656, Abiraterone
Sorrento Therapeutics, Inc.
Prostate Cancer, Prostate Cancer Metastatic
01/28
01/28
NCT02330367: Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC

Active, not recruiting
1/2
368
RoW
AC0010, AC0010MA
Hangzhou ACEA Pharmaceutical Research Co., Ltd., Guangdong Provincial People's Hospital, Acea Bio (Hangzhou) Co., Ltd.
Metastatic Non-small Cell Lung Cancer
12/22
03/23
Elyxyb (celecoxib) / Dr. Reddy’s, Collegium Pharma, Sorrento
NCT06997068: Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population

Not yet recruiting
2
25
US
Celecoxib, Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, Celebrex, Elyxyb, Onsenal, SC-58635, YM 177, Erlotinib Hydrochloride, CP 358, CP-358, Cp-358,774, CP358, OSI 774, OSI-774, OSI774, Tarceva, Imaging Procedure, Diagnostic Imaging Technique, Image Type, Imaging, Imaging (procedure), Imaging Procedures, Imaging Technique, imaging type, IMAGING_METHOD, imaging_type, Medical Imaging, Type of imaging, Interview, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Jylamvo, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Questionnaire Administration
Mayo Clinic
Metastatic Oral Cavity Carcinoma, Recurrent Oral Cavity Carcinoma, Stage IVC Lip and Oral Cavity Cancer AJCC v8
06/28
06/28
Enlituo (cetuximab biosimilar) / Mabpharm Limited, Sorrento
NCT03206151: CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer

Completed
3
520
RoW
CMAB009, Eribitux, Irinotecan, Camptosar, Folinic acid, leucovorin, 5-fluorouracil, Fluoroplex
Taizhou Mabtech Pharmaceutical Co.,Ltd
Metastatic Colorectal Cancer
05/22
05/22
Seprehvec (STI1386) / Sorrento
OV2-RRST-101, NCT05361954: Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors

Not yet recruiting
1b
36
NA
STI-1386, Seprehvec
Sorrento Therapeutics, Inc.
Cancer, Cancer of Pancreas, Sarcoma, Hepatic Metastasis, Solid Tumor
10/26
02/27
CMAB008 (infliximab biosimilar) / Mabpharm Limited, Sorrento, Shandong Kexing Bioproducts
NCT05906576: Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients

Recruiting
4
30
RoW
Infliximab, CMAB008
Taizhou Mabtech Pharmaceutical Co.,Ltd
Crohn Disease
11/26
02/27
Sertaly (trastuzumab botidotin) / Sichuan Kelun Pharma
KL166-Ⅲ-06, CTR20231740: A randomized, open-label, controlled, multicenter phase III trial of A166 for injection versus trastuzumab for injection (T-DM1) in patients with HER2-positive unresectable or metastatic breast cancer who have received prior trastuzumab and taxane therapy

Ongoing
3
357
China
trastuzumab botidotin (A166) - Sichuan Kelun Pharma, Kadcyla (ado-trastuzumab emtansine) - Roche
Sichuan Kelunbotai Biopharmaceutical Co., Ltd
HER2-positive unresectable or metastatic breast cancer
 
 
KL166-III-06, NCT06968585: A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy

Active, not recruiting
3
365
RoW
A166, T-DM1
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
HER2-positive Breast Cancer
11/25
03/28
KL166-II-02, CTR20212088: Phase II clinical study of injectable A166 for the treatment of end-line HER2-positive breast cancer patients

Completed
2
123
China
trastuzumab botidotin (A166) - Sichuan Kelun Pharma
Sichuan Kelunbotai Biopharmaceutical Co., Ltd.
HER2-positive unresectable locally advanced, recurrent or metastatic breast cancer
 
 
KL166-IIS-001, NCT05346328: HER2-positive Breast Cancer Project Initiated by Investigators

Not yet recruiting
2
48
NA
Injection of A166
Fudan University
Breast Cancer
12/23
12/24
NCT03602079: Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Completed
1/2
49
US
A166
Klus Pharma Inc.
HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer, Salivary Gland Cancer, Salivary Gland Tumor, Salivary Gland Carcinoma, Salivary Gland Neoplasms, Lung Cancer, Colo-rectal Cancer, Rare Diseases, Solid Tumor, Recurrent Gastric Cancer, Recurrent Colon Cancer, Recurrent Breast Cancer, Head and Neck Cancer, Head and Neck Carcinoma, Bladder Cancer, Cervical Cancer, Liver Cancer, Bile Duct Cancer, Urologic Cancer, Pancreatic Cancer, Prostate Cancer, Recurrent Prostate Cancer, Rectal Cancer, Recurrent Ovarian Carcinoma, Recurrent Renal Cell Cancer, Rectal Cancer Stage II, Rectal Cancer Stage I, Rectal Cancer Stage III, Skin Cancer, Mouth Cancer, Lip Cancer Stage I, Tongue Cancer, Breast Neoplasm Malignant Primary, Larynx Cancer, Tonsil Cancer, Palate Cancer, Mucoepidermoid Carcinoma, Primary Peritoneal Carcinoma, Mucinous Adenocarcinoma Gastric, Mucinous Breast Cancer Recurrent, Cholangiocarcinoma
01/22
01/22
KL166-Ⅰ-07, CTR20212950: Phase Ib clinical study of A166 for injection in patients with HER2-positive colorectal cancer

Recruiting
1b
60
China
trastuzumab botidotin (A166) - Sichuan Kelun Pharma
Sichuan Kelunbotai Biopharmaceutical Co., Ltd.
HER2-positive advanced malignant solid tumors
 
 
KL166-I-04, CTR20211319: A single-arm, open-label Phase Ib clinical study of Injectable A166 for the treatment of patients with unresectable locally advanced, recurrent, or metastatic urothelial carcinoma that overexpresses HER2 and have failed standard treatments.

Recruiting
1
74
China
trastuzumab botidotin (A166) - Sichuan Kelun Pharma
Unresectable locally advanced, recurrent, or metastatic urothelial carcinoma
 
 
KL166-I-01-CTP, NCT05311397: A Study of A166 in Patients With Advanced Solid Malignant Tumors

Recruiting
1
120
RoW
A166
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Breast Cancer
06/25
12/25
Ztlido 5.4% (lidocaine topical patch 5.4%) / Sorrento
NCT05096494: Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain

Completed
2
75
US
SP-103, Placebo
Scilex Pharmaceuticals, Inc., Worldwide Clinical Trials
Moderate to Severe Acute Lower Back Pain
05/23
05/23
IMC-001 / Immuneoncia Therap
DISTINKT, NCT04414163: A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

Active, not recruiting
2
23
RoW
IMC-001, Not confirm yet
ImmuneOncia Therapeutics Inc.
Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK/T-cell Lymphoma
07/24
02/26
NCT03999658: A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

Withdrawn
2
220
NA
STI-3031, IMC-001
Sorrento Therapeutics, Inc.
Peripheral T Cell Lymphoma, Diffuse Large B Cell Lymphoma, Biliary Tract Cancer, Extranodal NK T Cell Lymphoma, Nasal
01/24
07/24
TMB-H, NCT06365840: A Study of IMC-001 In Patients With Metastatic Or Locally Advanced Solid Tumor

Recruiting
2
30
RoW
IMC-001
ImmuneOncia Therapeutics Inc.
TMB-H, Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
12/26
08/29
NCT06788431: A Study of IMC-001 on Improved Atherosclerotic Plaque Stability in Patients of ACS

Recruiting
2
14
RoW
IMC-001, Optimal medical treatment
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd., The First Affiliated Hospital of Nanyang Medical College, Renji Hospital, Shanghai
Atherosclerosis
11/25
12/25
NeoChance, NCT04196465: Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers

Active, not recruiting
2
48
RoW
IMC-001
Asan Medical Center
Subjects With Resectable and Localized Gastric Cancer, Subjects With Resectable Esophageal Cancer or Liver Cancer, Subjects With Resectable Liver Cancer
09/26
09/26
NCT05653661: Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors

Withdrawn
1
40
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Nab-paclitaxel/Danburstotug Complex AP160, AP 160, AP-160, AP160, Nab-paclitaxel/STI-3031 Complex AP160
Mayo Clinic
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Melanoma
07/24
07/24
NCT05946226: A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors

Recruiting
1
18
RoW
IMC002 injection, Autologous Claudin 18.2 specific CAR-T cell injection
Suzhou Immunofoco Biotechnology Co., Ltd
Advanced Digestive System Tumor
12/25
12/25
Sofusa-2, NCT05393713: Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Study

Active, not recruiting
1
3
US
Anti-PD-L1 Monoclonal Antibody IMC-001, IMC 001, IMC-001, IMC001, STI 3031, STI-3031, STI3031, Punch Biopsy, BIOPSY, PUNCH, Punch Biopsy of Skin
Mayo Clinic
Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma, Metastatic Melanoma, Recurrent Metastatic Melanoma
01/26
01/26
STI-6129 / Sorrento
NCT04316442: Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis

Recruiting
1b/2a
60
US
STI-6129, anti-CD38-Duostatin 5.2 antibody-drug conjugate (ADC)
Sorrento Therapeutics, Inc.
Light Chain (AL) Amyloidosis
09/24
12/24
NCT05308225: Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

Active, not recruiting
1b/2a
72
US
STI-6129
Sorrento Therapeutics, Inc.
Multiple Myeloma
12/25
07/26
NCT05565807: Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

Recruiting
1/2
84
RoW
STI-6129
Zhejiang ACEA Pharmaceutical Co. Ltd.
Relapsed or Refractory Multiple Myeloma
03/25
02/27
NCT05584709: Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors

Not yet recruiting
1b
34
US
STI-6129, Anti-CD38 antibody drug conjugate
Sorrento Therapeutics, Inc.
Advanced Solid Tumor
08/25
10/25
NCT05519527: STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis

Withdrawn
1
62
NA
Part 1 (STI-6129), Part 2 (STI-6129)
M.D. Anderson Cancer Center
Refractory T Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia (AML)
02/23
02/23
NCT05692908: An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis

Withdrawn
1
36
NA
STI-6129, anti-CD38-Duostatin 5.2 antibody-drug conjugate (ADC)
Sorrento Therapeutics, Inc.
Light Chain (AL) Amyloidosis
09/24
11/24
Oqory (samtonadstrocel) / Sorrento
NCT04905836: Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress

Recruiting
2
60
US
COVI-MSC, Placebo
Sorrento Therapeutics, Inc.
Covid19
12/22
03/23
NCT04992247: Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise

Withdrawn
2
60
NA
COVI-MSC, Placebo
Sorrento Therapeutics, Inc.
Covid19
07/24
09/24
STI-6643 / Sorrento
NCT04900519: Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors

Recruiting
1
100
US
STI-6643
Sorrento Therapeutics, Inc.
Solid Tumor, Relapsed Solid Neoplasm, Refractory Tumor
12/24
03/25
OQY-3258 / Oqory
NCT06383767: A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Recruiting
3
378
RoW
ESG401, Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice)
Qilu Pharmaceutical Co., Ltd.
Metastatic Breast Cancer
06/27
07/28
NCT06732323: A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Not yet recruiting
3
504
RoW
ESG401, Investigator's Choice Chemotherapy
Qilu Pharmaceutical Co., Ltd.
Triple-Negative Breast Cancer (TNBC)
06/27
07/28
NCT06145308: Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Recruiting
2
10
RoW
Vedolizumab, larotinib or enttraitinib, antiandrogen drug treatment, leprerelin + bicalutamide ± Abiraterone 1000mg po qd, ESG401, small molecule multi-target tyrosine kinase inhibitors± Chemioterapy, apatinib or erlotinib, albumin paclitaxel with platinum, HR-positive group, PI3K mutant group, Homologous Recombination repair defect group, Nectin-4 ADC group, Ivoximab group, Apalolito vorellizumab group
Peking Union Medical College, Peking University Hospital of Stomatology
Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma, Neoadjuvant or Conversion Therapy, Precision Therapy
07/26
07/26
ESG401-101, NCT04892342: Study of ESG401 in Adults With Solid Tumors

Recruiting
1/2
177
RoW
ESG401
Shanghai Escugen Biotechnology Co., Ltd
Neoplasms, Breast, Neoplasms, Lung, Neoplasms,Colorectal, Neoplasms, Bladder, Neoplasm of Stomach, Neoplasms,Ovarian
10/25
12/25
STI-1492 / Sorrento
NCT05007418: Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

Recruiting
1b
54
US
STI-1492
Sorrento Therapeutics, Inc.
Multiple Myeloma
12/25
02/26
Ovydso (olgotrelvir) / Sorrento
NCT05716425: Study to Assess the Efficacy and Safety of STI-1558 in Adult Subjects With Mild or Moderate (COVID-19)

Completed
3
1218
RoW
STI-1558, STI-1558 placebo
Zhejiang ACEA Pharmaceutical Co. Ltd.
COVID-19
07/23
07/23
NCT05523739: Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients

Completed
1
79
RoW
STI-1558
Zhejiang ACEA Pharmaceutical Co. Ltd.
SARS-CoV-2 Infection
12/22
03/23
NCT05754411: [14C] Study on Mass Balance and Biotransformation of STI-1558 in Healthy Chinese Adult Male Subjects

Completed
1
6
RoW
[14C]STI-1558
Zhejiang ACEA Pharmaceutical Co. Ltd.
COVID-19
06/23
11/23
NCT06044233: A Bioequivalence Trial of Fasting Single Oral STI-1558 Capsule in Healthy Chinese Subjects

Completed
1
32
RoW
STI-1558, An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
Zhejiang ACEA Pharmaceutical Co. Ltd.
COVID-19
10/23
11/23
NCT05685719: A Study to Evaluate the Relative Bioavailability of STI-1558 and the Effect of Itraconazole and Rifampin on the Pharmacokinetics of STI-1558

Completed
1
37
RoW
STI-1558, Itraconazole, Rifampin
Zhejiang ACEA Pharmaceutical Co. Ltd.
COVID-19 Pneumonia
03/23
11/23
STI-9199 / Sorrento
No trials found
nab-paclitaxel/rituximab nanoparticle (AR160) / Sorrento
No trials found
bevacizumab/nab-paclitaxel (AB160) / Sorrento
No trials found
STI-2798 / Sorrento
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cynviloq (paclitaxel polymeric micelle formulation) / Sorrento, Samyang Group, ImmunityBio
Randomized study of Genexol-PM combined with Cisplatin in advanced NSCLC, ChiCTR-IPR-15006252: A Randomized, Open, Multicenter Trial of Genexol-PM or Paclitaxel Injection combined with Cisplatin for first-line therapy of advanced Non-Small Cell Lung Cancer(NSCLC)

Recruiting
3
426
 
Genexol-PM+Cisplatin ;Paclitaxel Injection + Cisplatin
Guangdong General Hospital; Shanghai Chest Hospital; Jiangsu Cancer Hospital; Shanghai Yizhong Bio-technology Co., Ltd, self-financing
Non-Small Cell Lung Cancer(NSCLC)
 
 
NCT07009925: Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.

Not yet recruiting
2
38
NA
Ivonescimab 20mg/kg intravenous every 3 weeks, paclitaxel polymeric micelles ≤300mg/㎡intravenous every 3 weeks, platinum intravenous every 3 weeks
Jiangsu Cancer Institute & Hospital
Squamous Cell Lung Cancer
05/27
05/28
ChiCTR-ONC-14005123: Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced tomors

Completed
1
12
 
Genexol-PM
Jiangsu Cancer Hospital; None, self-financing
advanced tumor
 
 
NCT06936787: An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa

Recruiting
1
21
RoW
IGT001
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Retinitis Pigmentosa
12/25
12/27
NCT05300828: Safety of Genexol PM and Carboplatin as First-line Therapy in Ovarian Cancer

Completed
N/A
600
RoW
Genexl PM
Seoul National University Hospital, Samyang Biopharmaceuticals Corporation
Ovarian Cancer
04/22
12/22
resiniferatoxin (MCP-101) / Sorrento
NCT04885972: Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis

Active, not recruiting
2
124
US
Resiniferatoxin, RTX, Zilretta, triamcinolone acetonide, Placebo
Sorrento Therapeutics, Inc.
Osteoarthritis, Knee, Knee Osteoarthritis, Knee Pain Chronic
09/23
11/23
NCT05067257: Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer

Suspended
2
120
US
Resiniferatoxin, RTX, Placebo
Sorrento Therapeutics, Inc.
Pain, Intractable, Pain Cancer, Pain
06/27
12/27
NCT00804154: Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

Recruiting
1
45
US
Intrathecal Resiniferatoxin
National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Neurological Disorders and Stroke (NINDS), Sorrento Therapeutics, Inc.
Intractable Pain, Palliative Care
02/26
02/26
ZTlido (lidocaine patch 1.8%) / Sorrento
DLss, NCT06030297: Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.

Recruiting
N/A
301
US
Diode Laser fiber type Selective Stimulator, DLss, ZTlido 1.8 % Topical System, PeriCam PSI NR, speckle imager, Medoc Quantitative Sensory Testing, QST, Inactive Topical System, placebo patch
University of Utah, Stanford University, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS)
Peripheral Neuropathy
08/25
08/25
Shan Ke Yu (socazolimab) / Lee's Pharm
NCT04359550: Study of ZKAB001 for Maintenance Therapy in Patients With High-grade Osteosarcoma After Adjuvant Chemotherapy

Not yet recruiting
3
362
NA
Recombinant human anti-PD-L1 monoclonal antibody (ZKAB001), placebo
Lee's Pharmaceutical Limited
High-grade Osteosarcoma
06/22
06/23
ZKAB001-LEES-2020-07, NCT04878016: A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC

Completed
3
498
RoW
ZKAB001, Placebo, Carboplatin, Etoposide
Lee's Pharmaceutical Limited
Extensive-stage Small-cell Lung Cancer
10/23
10/23
NCT06459687: Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer

Recruiting
3
440
RoW
Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab, Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab
Lee's Pharmaceutical Limited
Cervical Cancer
09/27
09/28
ChiCTR2000028785: A multicenter, phase III, randomized, double-blind, placebo-controlled trial for recombinant human anti-PD-L1 monoclonal antibody (ZKAB001) for maintenance therapy after adjuvant chemotherapy in patients with high-grade osteosarcoma

Not yet recruiting
3
362
 
Intravenous infusion ;Intravenous infusion
Shanghai Sixth People's Hospital; Zhaoke (Guangzhou) Oncology Drug Co., Ltd., Self-finacing
Osteosarcoma
 
 
NCT03676985: A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade Osteosarcoma

Recruiting
1/2
15
RoW
ZKAB001 5mg/kg, PD-L1 monoclonal antibody, ZKAB001 10mg/kg, ZKAB001 15mg/kg
Lee's Pharmaceutical Limited
Osteosarcoma
02/20
06/23
NCT03676946: A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma

Recruiting
1/2
15
RoW
ZKAB001 5mg/kg, PD-L1 monoclonal antibody, ZKAB001 10mg/kg, ZKAB001 15mg/kg
Lee's Pharmaceutical Limited
Urothelial Carcinoma
02/20
06/23
NCT04460066: A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.

Active, not recruiting
1/2
70
RoW
anti-PD-L1 antibody, ZKAB001, Socazolimab Injection, albumin bound paclitaxel, ABRAXANE, cisplatin, placebo, radical resection of esophageal carcinoma
Lee's Pharmaceutical Limited
Esophageal Cancer
12/21
07/23
NCT04849260: Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma

Recruiting
1/2
54
RoW
Pexa-Vec combined with ZKAB001, ZKAB001 monotherapy
Lee's Pharmaceutical Limited
Local Progression or Metastatic Melanoma With Failed First-line Treatment
05/22
05/23
ChiCTR1800016649: Phase I+II clinical study protocol of recombinant human anti-PD-L1 monoclonal antibody (ZKAB001)

Not yet recruiting
1
21
 
Intravenous infusion ;Intravenous infusion ;Intravenous infusion
the Sixth People's Hospital; Zhaoke (Guang Zhou) Oncology Pharmaceutical Limited, Self-finacing
Osteosarcoma
 
 
NCT03676959: A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Recurrent or Metastatic Cervical Cancer

Recruiting
1
101
RoW
ZKAB001 5mg/kg, PD-L1 monoclonal antibody, ZKAB001 10mg/kg, ZKAB001 15mg/kg
Lee's Pharmaceutical Limited
Cervical Cancer
05/22
10/22
NCT04603846: A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma

Active, not recruiting
1
20
RoW
anti-PD-L1 antibody, ZKAB001, albumin bound paclitaxel, ABRAXANE
Lee's Pharmaceutical Limited
Advanced Urothelial Carcinoma
10/22
08/23
NCT04346914: Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer

Recruiting
1
20
RoW
recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide
Lee's Pharmaceutical Limited
Extensive Stage Small Cell Lung Cancer
10/22
10/22
NCT04608786: A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer

Enrolling by invitation
1
10
RoW
ZKAB001 5mg/kg, PD-L1 monoclonal antibody, Capecitabine
Lee's Pharmaceutical Limited
Biliary Tract Cancer
12/22
12/23
ChiCTR2100042988: A single-arm, open phase Ib clinical study of ZKAB001 combined with capecitabine for adjuvant treatment of patients with malignant tumors of the biliary system

Recruiting
1
10
 
Regiments
Renji Hospital Affiliated to Medical College of Shanghai Jiaotong University; Renji Hospital Affiliated to Medical College of Shanghai Jiaotong University, Guangzhou Zhaoke Pharmaceutical Co., Ltd.
Malignant tumor of biliary system
 
 
Fujovee (abivertinib) / Sorrento
NCT03856697: Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

Not yet recruiting
3
406
RoW
Abivertinib Maleate Capsules, Placebo Gefitinib Tablets, Gefitinib Tablets, Placebo Abivertinib Maleate Capsules
Hangzhou ACEA Pharmaceutical Research Co., Ltd., Guangdong Provincial People's Hospital
Advanced Non-small Cell Lung Cancer
03/22
03/24
TRUMP, NCT03574402: Phase II Umbrella Study Directed by Next Generation Sequencing

Recruiting
2
400
RoW
Avitinib Maleate, AC0010, Afatinib, Giotrif, Crizotinib, Xalkori, X-396, ensartinib, Chidamide, Epidaza, Pyrotinib Maleate, SHR1258, AZD3759, Pirotinib, KBP-5209, Nimotuzumab, Pemetrexed, LY231514, Cisplatin, CDDP, Sintilimab, Gemcitabine, LY188011, Carboplatin, NSC 241240
Guangdong Association of Clinical Trials, Chinese Thoracic Oncology Group
Carcinoma, Non-Small-Cell Lung
12/22
12/24
Maverick, NCT05361915: Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer

Suspended
2
100
US
Abivertinib, STI-5656, Abiraterone
Sorrento Therapeutics, Inc.
Prostate Cancer, Prostate Cancer Metastatic
01/28
01/28
NCT02330367: Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC

Active, not recruiting
1/2
368
RoW
AC0010, AC0010MA
Hangzhou ACEA Pharmaceutical Research Co., Ltd., Guangdong Provincial People's Hospital, Acea Bio (Hangzhou) Co., Ltd.
Metastatic Non-small Cell Lung Cancer
12/22
03/23
Elyxyb (celecoxib) / Dr. Reddy’s, Collegium Pharma, Sorrento
NCT06997068: Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population

Not yet recruiting
2
25
US
Celecoxib, Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, Celebrex, Elyxyb, Onsenal, SC-58635, YM 177, Erlotinib Hydrochloride, CP 358, CP-358, Cp-358,774, CP358, OSI 774, OSI-774, OSI774, Tarceva, Imaging Procedure, Diagnostic Imaging Technique, Image Type, Imaging, Imaging (procedure), Imaging Procedures, Imaging Technique, imaging type, IMAGING_METHOD, imaging_type, Medical Imaging, Type of imaging, Interview, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Jylamvo, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Questionnaire Administration
Mayo Clinic
Metastatic Oral Cavity Carcinoma, Recurrent Oral Cavity Carcinoma, Stage IVC Lip and Oral Cavity Cancer AJCC v8
06/28
06/28
Enlituo (cetuximab biosimilar) / Mabpharm Limited, Sorrento
NCT03206151: CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer

Completed
3
520
RoW
CMAB009, Eribitux, Irinotecan, Camptosar, Folinic acid, leucovorin, 5-fluorouracil, Fluoroplex
Taizhou Mabtech Pharmaceutical Co.,Ltd
Metastatic Colorectal Cancer
05/22
05/22
Seprehvec (STI1386) / Sorrento
OV2-RRST-101, NCT05361954: Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors

Not yet recruiting
1b
36
NA
STI-1386, Seprehvec
Sorrento Therapeutics, Inc.
Cancer, Cancer of Pancreas, Sarcoma, Hepatic Metastasis, Solid Tumor
10/26
02/27
CMAB008 (infliximab biosimilar) / Mabpharm Limited, Sorrento, Shandong Kexing Bioproducts
NCT05906576: Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients

Recruiting
4
30
RoW
Infliximab, CMAB008
Taizhou Mabtech Pharmaceutical Co.,Ltd
Crohn Disease
11/26
02/27
Sertaly (trastuzumab botidotin) / Sichuan Kelun Pharma
KL166-Ⅲ-06, CTR20231740: A randomized, open-label, controlled, multicenter phase III trial of A166 for injection versus trastuzumab for injection (T-DM1) in patients with HER2-positive unresectable or metastatic breast cancer who have received prior trastuzumab and taxane therapy

Ongoing
3
357
China
trastuzumab botidotin (A166) - Sichuan Kelun Pharma, Kadcyla (ado-trastuzumab emtansine) - Roche
Sichuan Kelunbotai Biopharmaceutical Co., Ltd
HER2-positive unresectable or metastatic breast cancer
 
 
KL166-III-06, NCT06968585: A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy

Active, not recruiting
3
365
RoW
A166, T-DM1
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
HER2-positive Breast Cancer
11/25
03/28
KL166-II-02, CTR20212088: Phase II clinical study of injectable A166 for the treatment of end-line HER2-positive breast cancer patients

Completed
2
123
China
trastuzumab botidotin (A166) - Sichuan Kelun Pharma
Sichuan Kelunbotai Biopharmaceutical Co., Ltd.
HER2-positive unresectable locally advanced, recurrent or metastatic breast cancer
 
 
KL166-IIS-001, NCT05346328: HER2-positive Breast Cancer Project Initiated by Investigators

Not yet recruiting
2
48
NA
Injection of A166
Fudan University
Breast Cancer
12/23
12/24
NCT03602079: Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Completed
1/2
49
US
A166
Klus Pharma Inc.
HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer, Salivary Gland Cancer, Salivary Gland Tumor, Salivary Gland Carcinoma, Salivary Gland Neoplasms, Lung Cancer, Colo-rectal Cancer, Rare Diseases, Solid Tumor, Recurrent Gastric Cancer, Recurrent Colon Cancer, Recurrent Breast Cancer, Head and Neck Cancer, Head and Neck Carcinoma, Bladder Cancer, Cervical Cancer, Liver Cancer, Bile Duct Cancer, Urologic Cancer, Pancreatic Cancer, Prostate Cancer, Recurrent Prostate Cancer, Rectal Cancer, Recurrent Ovarian Carcinoma, Recurrent Renal Cell Cancer, Rectal Cancer Stage II, Rectal Cancer Stage I, Rectal Cancer Stage III, Skin Cancer, Mouth Cancer, Lip Cancer Stage I, Tongue Cancer, Breast Neoplasm Malignant Primary, Larynx Cancer, Tonsil Cancer, Palate Cancer, Mucoepidermoid Carcinoma, Primary Peritoneal Carcinoma, Mucinous Adenocarcinoma Gastric, Mucinous Breast Cancer Recurrent, Cholangiocarcinoma
01/22
01/22
KL166-Ⅰ-07, CTR20212950: Phase Ib clinical study of A166 for injection in patients with HER2-positive colorectal cancer

Recruiting
1b
60
China
trastuzumab botidotin (A166) - Sichuan Kelun Pharma
Sichuan Kelunbotai Biopharmaceutical Co., Ltd.
HER2-positive advanced malignant solid tumors
 
 
KL166-I-04, CTR20211319: A single-arm, open-label Phase Ib clinical study of Injectable A166 for the treatment of patients with unresectable locally advanced, recurrent, or metastatic urothelial carcinoma that overexpresses HER2 and have failed standard treatments.

Recruiting
1
74
China
trastuzumab botidotin (A166) - Sichuan Kelun Pharma
Unresectable locally advanced, recurrent, or metastatic urothelial carcinoma
 
 
KL166-I-01-CTP, NCT05311397: A Study of A166 in Patients With Advanced Solid Malignant Tumors

Recruiting
1
120
RoW
A166
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Breast Cancer
06/25
12/25
Ztlido 5.4% (lidocaine topical patch 5.4%) / Sorrento
NCT05096494: Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain

Completed
2
75
US
SP-103, Placebo
Scilex Pharmaceuticals, Inc., Worldwide Clinical Trials
Moderate to Severe Acute Lower Back Pain
05/23
05/23
IMC-001 / Immuneoncia Therap
DISTINKT, NCT04414163: A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

Active, not recruiting
2
23
RoW
IMC-001, Not confirm yet
ImmuneOncia Therapeutics Inc.
Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK/T-cell Lymphoma
07/24
02/26
NCT03999658: A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies

Withdrawn
2
220
NA
STI-3031, IMC-001
Sorrento Therapeutics, Inc.
Peripheral T Cell Lymphoma, Diffuse Large B Cell Lymphoma, Biliary Tract Cancer, Extranodal NK T Cell Lymphoma, Nasal
01/24
07/24
TMB-H, NCT06365840: A Study of IMC-001 In Patients With Metastatic Or Locally Advanced Solid Tumor

Recruiting
2
30
RoW
IMC-001
ImmuneOncia Therapeutics Inc.
TMB-H, Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
12/26
08/29
NCT06788431: A Study of IMC-001 on Improved Atherosclerotic Plaque Stability in Patients of ACS

Recruiting
2
14
RoW
IMC-001, Optimal medical treatment
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd., The First Affiliated Hospital of Nanyang Medical College, Renji Hospital, Shanghai
Atherosclerosis
11/25
12/25
NeoChance, NCT04196465: Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers

Active, not recruiting
2
48
RoW
IMC-001
Asan Medical Center
Subjects With Resectable and Localized Gastric Cancer, Subjects With Resectable Esophageal Cancer or Liver Cancer, Subjects With Resectable Liver Cancer
09/26
09/26
NCT05653661: Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors

Withdrawn
1
40
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Nab-paclitaxel/Danburstotug Complex AP160, AP 160, AP-160, AP160, Nab-paclitaxel/STI-3031 Complex AP160
Mayo Clinic
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Melanoma
07/24
07/24
NCT05946226: A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors

Recruiting
1
18
RoW
IMC002 injection, Autologous Claudin 18.2 specific CAR-T cell injection
Suzhou Immunofoco Biotechnology Co., Ltd
Advanced Digestive System Tumor
12/25
12/25
Sofusa-2, NCT05393713: Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Study

Active, not recruiting
1
3
US
Anti-PD-L1 Monoclonal Antibody IMC-001, IMC 001, IMC-001, IMC001, STI 3031, STI-3031, STI3031, Punch Biopsy, BIOPSY, PUNCH, Punch Biopsy of Skin
Mayo Clinic
Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma, Metastatic Melanoma, Recurrent Metastatic Melanoma
01/26
01/26
STI-6129 / Sorrento
NCT04316442: Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis

Recruiting
1b/2a
60
US
STI-6129, anti-CD38-Duostatin 5.2 antibody-drug conjugate (ADC)
Sorrento Therapeutics, Inc.
Light Chain (AL) Amyloidosis
09/24
12/24
NCT05308225: Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

Active, not recruiting
1b/2a
72
US
STI-6129
Sorrento Therapeutics, Inc.
Multiple Myeloma
12/25
07/26
NCT05565807: Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

Recruiting
1/2
84
RoW
STI-6129
Zhejiang ACEA Pharmaceutical Co. Ltd.
Relapsed or Refractory Multiple Myeloma
03/25
02/27
NCT05584709: Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors

Not yet recruiting
1b
34
US
STI-6129, Anti-CD38 antibody drug conjugate
Sorrento Therapeutics, Inc.
Advanced Solid Tumor
08/25
10/25
NCT05519527: STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis

Withdrawn
1
62
NA
Part 1 (STI-6129), Part 2 (STI-6129)
M.D. Anderson Cancer Center
Refractory T Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia (AML)
02/23
02/23
NCT05692908: An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis

Withdrawn
1
36
NA
STI-6129, anti-CD38-Duostatin 5.2 antibody-drug conjugate (ADC)
Sorrento Therapeutics, Inc.
Light Chain (AL) Amyloidosis
09/24
11/24
Oqory (samtonadstrocel) / Sorrento
NCT04905836: Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress

Recruiting
2
60
US
COVI-MSC, Placebo
Sorrento Therapeutics, Inc.
Covid19
12/22
03/23
NCT04992247: Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise

Withdrawn
2
60
NA
COVI-MSC, Placebo
Sorrento Therapeutics, Inc.
Covid19
07/24
09/24
STI-6643 / Sorrento
NCT04900519: Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors

Recruiting
1
100
US
STI-6643
Sorrento Therapeutics, Inc.
Solid Tumor, Relapsed Solid Neoplasm, Refractory Tumor
12/24
03/25
OQY-3258 / Oqory
NCT06383767: A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Recruiting
3
378
RoW
ESG401, Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice)
Qilu Pharmaceutical Co., Ltd.
Metastatic Breast Cancer
06/27
07/28
NCT06732323: A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Not yet recruiting
3
504
RoW
ESG401, Investigator's Choice Chemotherapy
Qilu Pharmaceutical Co., Ltd.
Triple-Negative Breast Cancer (TNBC)
06/27
07/28
NCT06145308: Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Recruiting
2
10
RoW
Vedolizumab, larotinib or enttraitinib, antiandrogen drug treatment, leprerelin + bicalutamide ± Abiraterone 1000mg po qd, ESG401, small molecule multi-target tyrosine kinase inhibitors± Chemioterapy, apatinib or erlotinib, albumin paclitaxel with platinum, HR-positive group, PI3K mutant group, Homologous Recombination repair defect group, Nectin-4 ADC group, Ivoximab group, Apalolito vorellizumab group
Peking Union Medical College, Peking University Hospital of Stomatology
Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma, Neoadjuvant or Conversion Therapy, Precision Therapy
07/26
07/26
ESG401-101, NCT04892342: Study of ESG401 in Adults With Solid Tumors

Recruiting
1/2
177
RoW
ESG401
Shanghai Escugen Biotechnology Co., Ltd
Neoplasms, Breast, Neoplasms, Lung, Neoplasms,Colorectal, Neoplasms, Bladder, Neoplasm of Stomach, Neoplasms,Ovarian
10/25
12/25
STI-1492 / Sorrento
NCT05007418: Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

Recruiting
1b
54
US
STI-1492
Sorrento Therapeutics, Inc.
Multiple Myeloma
12/25
02/26
Ovydso (olgotrelvir) / Sorrento
NCT05716425: Study to Assess the Efficacy and Safety of STI-1558 in Adult Subjects With Mild or Moderate (COVID-19)

Completed
3
1218
RoW
STI-1558, STI-1558 placebo
Zhejiang ACEA Pharmaceutical Co. Ltd.
COVID-19
07/23
07/23
NCT05523739: Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients

Completed
1
79
RoW
STI-1558
Zhejiang ACEA Pharmaceutical Co. Ltd.
SARS-CoV-2 Infection
12/22
03/23
NCT05754411: [14C] Study on Mass Balance and Biotransformation of STI-1558 in Healthy Chinese Adult Male Subjects

Completed
1
6
RoW
[14C]STI-1558
Zhejiang ACEA Pharmaceutical Co. Ltd.
COVID-19
06/23
11/23
NCT06044233: A Bioequivalence Trial of Fasting Single Oral STI-1558 Capsule in Healthy Chinese Subjects

Completed
1
32
RoW
STI-1558, An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
Zhejiang ACEA Pharmaceutical Co. Ltd.
COVID-19
10/23
11/23
NCT05685719: A Study to Evaluate the Relative Bioavailability of STI-1558 and the Effect of Itraconazole and Rifampin on the Pharmacokinetics of STI-1558

Completed
1
37
RoW
STI-1558, Itraconazole, Rifampin
Zhejiang ACEA Pharmaceutical Co. Ltd.
COVID-19 Pneumonia
03/23
11/23
STI-9199 / Sorrento
No trials found
nab-paclitaxel/rituximab nanoparticle (AR160) / Sorrento
No trials found
bevacizumab/nab-paclitaxel (AB160) / Sorrento
No trials found
STI-2798 / Sorrento
No trials found

Download Options